UPLC-MS/MS Based Identification and Quantification of a Novel Dual Orexin Receptor Antagonist in Plasma Samples by Validated SWGTOX Guidelines

Lemborexant (LEM) is a novel dual orexin receptor antagonist (DORA), recently approved for the treatment of insomnia. As with other DORAs, LEM has potential of abuse and therefore placed in Schedule IV class by the United States Drug Enforcement Administration (USDEA). In this study, a sensitive and...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Muzaffar, Alshememry, Abdullah, Imam, Faisal, Kalam, Mohd Abul, Akhtar, Ali, Ali, Essam A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959124/
https://www.ncbi.nlm.nih.gov/pubmed/36850983
http://dx.doi.org/10.3390/toxics11020109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959124/
https://www.ncbi.nlm.nih.gov/pubmed/36850983
http://dx.doi.org/10.3390/toxics11020109

Ejemplares similares